Reynald Castaneda

Roche disclosed on Wednesday it had cut several early- to mid-stage candidates after a broader R&D review, which also saw pipeline additions and triggered recently-announced acquisitions and partnerships.

Plus, Ocular Therapeutix's private placement, LimmaTech Biologics' shigellosis vaccine data and a collaboration between Hox Therapeutics and Vernalis.

Plus, news about Cogent and Indivior: Karuna delays some KarXT readouts: As the drugmaker awaits closing of its large exit to Bristol Myers

Boehringer Ingelheim said on Monday that its “double G” metabolic dysfunction-associated steatohepatitis (MASH) drug delivered positive top-line results in a Phase II trial.

Moderna has made cuts at its Burlington and Norwood sites in Massachusetts, a spokesperson confirmed to Endpoints News , including some workers in quality assurance.

Novo Nordisk spelled out how it will try to catch up with the extraordinary demand for its GLP-1 drugs, underscoring its rationale for its in-house

Spruce Biosciences' tildacerfont failed a Phase IIb test in adults with congenital adrenal hyperplasia (CAH) due to compliance issues, crushing its stock $SPRB by as much as 75% premarket.

With Lonza anticipating persistent increase in demand for commercial biologics manufacturing, the Swiss company is picking up a production site owned by Roche's Genentech for $1.2 billion in cash.

Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year.

Sanofi, Pfizer and AstraZeneca separately pledged to increase their footprint in France, with investments adding up to almost €2 billion.